Melanoma Coverage from Every Angle
Advertisement
Advertisement

John A. Thompson, MD, and Anthony J. Olszanski, RPh, MD, on Melanoma: Expert Perspectives on the Best Adjuvant Regimen

Posted: Thursday, April 12, 2018

John A. Thompson, MD, of the University of Washington Fred Hutchinson Cancer Research Center, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss study findings on adjuvant ipilimumab (3 or 10 mg/kg) vs high-dose interferon alfa-2b for resected high-risk melanoma.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.